Evaluation of ticarcillin/clavulanic acid versus ceftriaxone plus amikacin for fever and neutropenia in pediatric patients with leukemia and lymphoma by Petrilli, Antonio Sergio et al.
BJID 2003; 7 (April) 111
Evaluation of Ticarcillin/Clavulanic Acid Versus Ceftriaxone Plus Amikacin for
Fever and Neutropenia in Pediatric Patients With Leukemia and Lymphoma
Antonio Sérgio Petrilli, Monica Cypriano, Pediatric Oncology Institute (GRAACC)
Lenice Silva Dantas, Lúcia Martino Lee, Division of Infectious Disease, Federal
Maria  Flávio Augusto Vercillo Luisi, University of São Paulo (UNIFESP), São
Katia Veronica Torres B. Silva (in memoriam) Paulo/SP, Brazil
and Carlos Alberto Pires Pereira
Background. The empirical use of antibiotic treatments is widely accepted as a means to treat
cancer patients in chemotherapy who have fever and neutropenia. Intravenous monotherapy, with
broad spectrum antibiotics, of patients with a high risk of complications is a possible alternative.
Methods. We conducted a prospective open-label, randomized study of patients with lymphoma or
leukemia who had fever and neutropenia during chemotherapy. Patients received either
monotherapy with ticarcillin/clavulanic acid (T) or ceftriaxone plus amikacin (C+A). Results.
Seventy patients who presented 136 episodes were evaluated, 68 in each arm of the study. The
mean neutrophil counts at admission were 217cells/mm3 (T) and 201cells/mm3 (C+A). The mean
duration of neutropenia was 8.7 days (T) and 7.6 days (C+A). Treatment was successful without
the need for modifications in 71% of the episodes in the T group and 81% in the C+A group
(p=0.23). Treatment was considered to have failed because of death in two episodes (3%) in the T
group and three episodes (4%) in the C+A group, and because of a change in the drug applied in
one episode in the T group and two episodes in the C+A group. Overall success was 96% (T) and
93% (C+A). Adverse events that occurred in group T were not related to the drugs used in this
study. Conclusion. In pediatric and adolescent patients with leukemia or lymphoma, who presented
with fever and neutropenia, during chemotherapy, ticarcillin/clavulanic acid was as successful as
the combination of ceftriaxone plus amikacin. It should be considered an appropriate option for
this group of patients at high risk for infections.
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Empirical antibiotic treatment of cancer patients
who develop fever and neutropenia is widely
accepted [1-4].
Our experience during the last 10 years has permitted
us to classify patients with fever and neutropenia into
high and low-risk groups for infectious complications,
according to the underlying disease. Patients with
leukemia and stage III and IV lymphomas were
considered to be at a higher risk than patients with solid
tumors and stage I and II lymphomas. For the initial
empirical treatment of fever and neutropenia, we had
previously established the use of ceftriaxone plus
amikacin for the high-risk group and ceftriaxone (IV)
or ciprofloxacin (PO), in an ambulatory setting, for the
low-risk group [5-9].
Ticarcillin is a wide spectrum semi-synthetic
penicillin, susceptible to inactivation by several beta-
lactamases, while clavulanic acid is an antagonist of
the beta-lactamases, avoiding enzymatic degradation
of the beta-lactam antibiotics by various species of
bacteria [10,11].
When used simultaneously, clavulanic acid expands
the antibacterial spectrum of ticarcillin, acting against
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beta-lactamases produced by Staphylococcus aureus,
Gram-negative bacteria, such as Klebsiella sp.,
Enterobacter sp., Serratia sp., some species of
Pseudomonas aeruginosa and anaerobic bacteria,
such as Bacteroides fragilis [12,13].
The aim of this study was to compare the efficacy
and toxicity of monotherapy with ticarcillin/clavulanic
acid versus ceftriaxone plus amikacin in children and
adolescents with leukemia and stage III or IV
lymphoma with fever and neutropenia.
Materials and Methods
This was a prospective randomized open-label trial
in pediatric and adolescent patients conducted at
Pediatric Oncology Institute – GRAACC – Federal
University of São Paulo – Brazil. The University
Institutional Ethical Review Board approved this protocol,
and written consent forms from the parents or legal
guardians of all patients were obtained beforehand.
The eligible population included children and
adolescents with leukemia and stage III & IV Hodgkin
and non-Hodgkin lymphomas that presented with fever
and neutropenia. Fever was defined as axillary
temperature higher or equal to 38ºC or higher than
37.5ºC on three separate occasions measured at four-
hour intervals within a period of 24 hours. Neutropenia
was defined as an absolute neutrophils count (ANC)
< 500 cells/mm3 or between 500 and 1000 before the
nadir of chemotherapy. Patients who developed fever
during transfusion of blood products or administration
of amphotericin B were not eligible.
Initial Evaluation. All patients were evaluated by
medical history, complete physical exam and the
following laboratory examinations: complete blood cell
count, electrolytes, liver and renal function, urinalysis,
urine and blood cultures, culture of suspicious lesions
or secretions, chest and sinus X-rays. Cerebrospinal
fluid was obtained from patients with seizures and/or
an abnormal neurological exam.
Randomization. All high-risk patients who developed
fever and neutropenia were randomly assigned to receive
either Ticarcillin/Clavulanic acid (T) or ceftriaxone plus
amikacin (C+A). T was given intravenously at a dose of
250 mg/kg/day (6 g/m2/day) in 4 doses. Ceftriaxone
was given at 100 mg/kg/day (3 g/m2/day) and amikacin
at 15 mg/kg/day as an intravenous infusion (BID).
Randomization of the treatment group was made using
a random number table.
Patients were evaluated daily by physical examination,
complete blood count, and weekly electrolyte, hepatic
and renal function tests. Blood cultures were obtained
on each day that the patient remained febrile. Chest X-
rays were made when clinically indicated. At 72 h of
hospitalization, the investigator classified the patients
according to the type of infection.
Therapy was modified by including new antibiotics,
antifungal or antiviral agents due to a change in the
clinical status, occurrence of other clinically documented
infection, persistence of fever or identification of a
resistant bacterium. Amphotericin B was started when
a patient persisted with fever and neutropenia for more
than 7 days, or earlier when fungal infection was
suspected or documented. Treatment was continued
until resolution of neutropenia, defined as an ANC >
500 cells/mm3 or until completion of an appropriate
course of therapy for a defined clinical or
microbiological infection.
Bacteriological isolates were identified according to
standard techniques and antibiotic susceptibilities were
determined by the disk diffusion method according to
recommendations of the National Committee for
Clinical Laboratory Standards [14].
Diagnostic Criteria and Outcome. The febrile episodes
were classified into the following groups: 1.
Microbiologically documented infection including
bacteremia; 2. Clinically documented infection and 3.
Fever of undetermined origin (FUO) due to a possible
infection (no clinical or microbiological evidence).
The clinical outcome of response of each episode
was evaluated both at 72 h and after completion of
antibiotic therapy.
Therapeutic success was defined as recovery from
the episode of fever and neutropenia, with or without
modification of the initial empirical antibacterial therapy
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[15]. Therapeutic failure was defined as discontinuation
of the study drug and/or death resulting from a
documented or presumed infection during the
neutropenic episode.
Statistical Analysis. The groups were compared through
an association test by the Chi-square method with the
Yates correction for qualitative variables and for the
quantitative variables; the Student-t test was used to
compare the averages of two independent samples;
the Mann-Whitney test was used instead when the
suppositions of the Student-t test were not satisfied.
To evaluate the suppositions of the Student-t test, the
following tests were used: a) Ryan-Joiner test (to test
normality) b) Bartlett’s test (to evaluate the homogeneity
of the variances between the different groups). A p-
value < 0.05 was considered significant.
Results
From December 1994 to October 1996, 70 patients
were registered; they presented 138 episodes of fever
and neutropenia. The study was conducted with 68
episodes in the T group and 68 episodes in the C+A
group. Two episodes, one in each group, were
excluded, one because of protocol violation and another
because the ANC never fell below 500 cells/mm3 after
the initial therapy.
The age of the patients ranged from 7 months to
17.5 years, with a mean age of 6.4 years (SD=3.96)
in the C+A group, and from 4 to 17.4 years, with an
average of 7.0 years (SD=4.1) in the T group. The
patients characteristics, including underlying disease,
disease status, age, sex, race, weight, height,
concomitant medication, medical or surgical condition
and neutrophil count at the time of randomization were
recorded (Tables 1 and 2); the two groups were similar.
All but two patients received chemotherapy
previous to entering the study. These two episodes
occurred in patients with active leukemia and
neutropenia at diagnosis. The underlying disease was
in remission in 48 (73%) and active in 20 (27%) of the
episodes that received C+A and 45 (66%) in remission
and 23 (34%) active in the T group (p=0.45).
In the general evaluation at the end of treatment
(Table 3), 64 episodes (47.2%) were classified as
clinically documented infection (27 in the C+A group
and 37 in the T group) and 36 (26.4%)
microbiologically documented infection (17 in the C+A
group and 19 in the T group), comprising 100 (73.6%)
episodes of documented infections in both groups.
Fever of unknown origin occurred in 36 (26.4) episodes
(24 in the C+A group and 12 in the T group).
Secondary infections (those diagnosed after 72
hours of treatment) occurred in 9% of the C+A group
and in 10% of the T group. All secondary infections
were microbiologically documented.
The average defervescence time was 1.9 days in
the C+A group (range 1 to 8 days) and 3.1 days in the
T group (range 1 to 15 days) (p=0.125). The mean
duration of neutropenia was 7.6 days in the C+A group
(range 1 to 30 days) and 8.7 days in the T group (range
1 to 28 days) (p=0.332).
Within the clinically documented infections there was
a predominance of infections in the head and neck area
(throat, ears, nose, eyes, and sinus in both groups); 29
(43%) episodes in the C+A group and 30 (44%) in
the T group (Table 4). Some of the patients presented
more than one focus of simultaneous infection. There
was no significant association between the site of
clinically documented infections and the therapy group.
Initial blood cultures were positive within 72 h in 8/
68 cases (11.7%) in the C+A group and in 5/68
episodes (7.3%) in the T group (Tables 5 and 6). During
this period, no fungal infection was isolated and Gram-
positive bacteremias were the most frequent in both
groups (75 and 60%). After 72 h of treatment, 11.8%
(8/68 cases) positive blood cultures were recovered
in the C+A group and 10.3% (7/68 cases) in the T
group, with a predominance of Gram-negative bacteria
(50%) in the C+A group and fungi (42.8%) in the T
group (Table 5). The bloodstream was considered the
primary site of infection in 18% (12/68 cases) of the
C+A group and in 12% (8/68 cases) of the T group
(Tables 4 - 6). More than one agent was isolated in
some cases.
Among all positive blood cultures, 13 (46.4%)
Gram-positive bacteria, 10 (35.7%) Gram-negative
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Table 1. Average, standard deviation (SD), minimum and maximum values for weight, age, height and initial
neutrophil counts, according to therapy groups
Table 2. Number and percentage of patients, according to several variables and therapy type
Ticarcillin versus Ceftri/Amika for Fever/Neutropenia
Ceftriaxone + Amikacin Ticarcillin/Clavulanic acid
Average (SD) Min-Max Average (SD) Min-Max p*
Weight (kg)  22.0 (10.2) 6.5 – 54.0 22.1 (10.3) 7.2 – 57.4 0.959
Age (months)  77.3 (47.6) 7 – 210 84.4 (50.0) 4 – 209 0.397
Height (cm)  112.4 (21.7) 61 – 182 114.1 (23.2) 70 – 176 0.667
Neutrophils (/mm3)  201.2 (165.0) 22 – 481 217.0 (157.0) 11 – 440 0.867
*Student’s T test.
C + A T Total
Variable  n % n % n % p*
Diagnosis ALL 40 58 37 6 77 57 0.865
AML 14 21 14 21 28 21
Hodgkin´s III 2 3 1 1 3 2
Hodgkin´s IV 1 1 1 1
Non Hodgkin´s III 9 13 10 13 19 13
Non Hodgkin´s IV 3 5 5 8 8 6
Disease activity Remission 48 73 45 66 93 69 0.453
Activity 20 27 23 34 43 31
Prior antimicrobial
treatment Yes 60 88 56 82 116 85 0.467
No 8 12 12 18 20 15
Gender Male 35 51 33 49 68 50 0.864
Female 33 49 35 51 68 50
Race Latin 53 78 59 87 112 82 0.300
Caucasian 1 1 - - 1 1
Black 14 21 9 13 23 17
Concomitant
medication Yes 65 96 65 96 130 96 0.676
No 3 4 3 4 6 4
Medical or surgical
condition Yes 4 6 4 6 8 6 0.716
No 64 94 64 94 128 94
Total 68 100 68 100 136 100
* Chi-square.
BJID 2003; 7 (April) 115
Table 3. Initial (72h) and overall evaluation by type of infection and treatment
Table 4. Primary site of infection according to therapy groups, analysed at 72h
Table 5. Positive blood cultures according to therapy group and time of isolation
Ticarcillin versus Ceftri/Amika for Fever/Neutropenia
Ceftriaxone + Amikacin Ticarcillin/Clavulanic acid
Up to 72h After 72h Up to 72h After 72h Total
N (%) N (%) N (%) N (%) N (%)
FUO 28 (41) 24 (35) 19 (28) 12 (18)  36 (26.4)
Clinically Documented 29 (43) 27 (40) 37 (54) 37 (54)  64 (47.2)
Microbiologically Documented 11 (16) 17 (25) 12 (18) 19 (28)  36 (26.4)
Total 68 (100) 68 (100) 68 (100) 68 (100) 136 (100.0)
FUO: Fever of unknown origin.
 C + A T Total
Site of infection N (%) N (%) N (%)
TENES 29 (43) 30 (44) 59 (43)
Urinary tract 3 (4) 5 (7) 8 (6)
Blood 12 (18) 8 (12) 20 (15)
Respiratory 7 (10) 9 (13) 16 (12)
Gastrointestinal tract 5 (7) 3 (4) 8 (6)
Skin 4 (6) 11 (16) 15 (11)
Mucositis 15 (22) 16 (24) 31 (23)
Others 5 (8)  6 (9) 11 (8)
Total episodes 68 (100) 68 (100) 136 (100)
TENES: throat, ears, nose, eyes, sinus.
Ceftriaxone + Amikacin Ticarcillin/Clavulanic acid
Up to 72hs After 72hs Up to 72hs After 72hs
Isolated Agent N (%) N (%) N (%) N (%)
Gram-positive 6 (75.0) 2 (25.0) 3 (60.0) 2 (28.6)
Gram-negative 2 (25.0) 4 (50.0) 2 (40.0) 2 (28.6)
Fungi 0 (0.0) 2 (25.0) 0 (0.0) 3 (42.8)
Total 8 (100.0) 8 (100.0) 5 (100.0) 7 (100.0)
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Table 6. Isolated pathogens according to time, initial therapy and sites of isolation
bacteria and 5 (17.9%) fungi were isolated (Table 6).
In 24 (18%) of the 136 episodes, an indwelling central
venous catheter was present (20 of a port-a-cath type).
Of these, 12 cases were randomly assigned to the C+A
group, and 8 to the T group.
Adverse events were observed in 21 (15%) episodes,
10 in the C+A group and 11 in T (p=1.000). The main
adverse effects were gastritis, arterial hypertension,
diarrhea, and vomiting. There was no correlation of the
type of adverse event with the drugs used.
Some antimicrobial agents were added to the initial
treatment in 33 (24.2%) episodes, 13 (19%) of the
C+A group and 20 (29%) of the T group (Table 7). In
the C+A group, modification of therapy was indicated
by clinical deterioration in 6 (46.1%), identification of
a resistant microorganism to the drugs being studied in
3 (23%) and both in 4 (30.7%). In the T group,
modification of therapy was based on clinical
deterioration in 13 (65%) cases, identification of a
resistant microorganism in 4 (15%) and both in 3 (15%).
The changes in the antibiotics were four times more
frequent in the microbiologically documented infections.
There was no significant relationship between the
reason that motivated the change in the therapeutic
procedure and the groups being evaluated. Table 7
shows which drugs were added according to the
treatment group. More than one addition was possible
in each episode. The most frequently added drugs were
amphotericin B (16.2%) and vancomycin (13.2%).
There was no significant difference between the two
groups in therapeutic success (p = 1.000), disease
status (p = 0.286) or the presence of fever (p = 0.156)
Ticarcillin versus Ceftri/Amika for Fever/Neutropenia
Ceftriaxone + Amikacin Ticarcillin/Clavulanic acid
Gram-positive Cocci: 18 (41.8%)
Within 72h After 72h Within 72h After 72h
Streptococcus sp. (bl) (2) S.CoN (bl) (2) S.CoN (bl) (1) S. aureus (skin) (1)
Citrobacter freundi (bl) (1) S. aureus (skin) (3) Enterococcus sp. (th) (1)
S. aureus (bl) (1) Streptococcus mitis (bl) (1) S.aureus (bl) (1)
S.CoN (bl) (1) S. aureus (bl) (1) S.CoN (bl) (1)
Enterococcus sp. (bl) (1)
Total 8 (42.1%) Total 10 (41.7%)
Gram-negative Bacilli: 20 (46.5%)
Escherichia coli (u) (2) Salmonella sp. (bl) (1) Escherichia coli (abs) (2) Escherichia coli (u) (1)
Enterobacter sp. (bl) (1) Klebsiella sp. (bl) (2) Klebsiella sp. (bl) (2) Escherichia coli (bl) (1)
Escherichia coli (bl) (1) Klebsiella sp. (u) (1) Escherichia coli (u) (2) Sthenotrophomonas
Escherichia coli (bl) (1) Enterobacter sp. (abs) (1)     maltophilia (bl) (1)
Proteus mirabilis (u) (1)
Total 9 (47.4%) Total 11 (45.80%)
Fungi : 5 (11.7%)
Candida guilliermondii (bl) (2) Candida albicans (bl) (1)
Rhodotorula
    glutimis (bl) (1)
Candida
    guilliermondii (bl) (1)
Total 2 (10.5%) Total 3 (12.5%)
Total 43 (100.0%)
Legend: bl = blood; u = urine; abs = abscess; g = gastrointestinal; th= throat, S.CoN = Sthaphylococcus Coagulase Negative.
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Table 7. Drug modification of initial therapy according to study group
Table 8. Status of the infection at the end of treatment
Table 9. Overall response to initial therapy
Ticarcillin versus Ceftri/Amika for Fever/Neutropenia
 C + A T Total
Associated drugs N (%) N (%) N (%)
Amphotericin B 7 (10.2) 15 (21.6) 22 (16.2)
Vancomycin 7 (10.3) 11 (16.2) 18 (13.2)
Clindamycin 2 (2.9) 3 (4.4) 5 (3.7)
Metronidazole 5 (7.3) 1 (1.5) 6 (4.4)
Others 7 (11.8) 5 (7.3) 13 (9.6)
Total 28 (41.2) 35 (51.5) 63 (46.3)
Episodes with addition 13 (19.0) 20 (29.0) 33 (24.2)
Episodes without addition 55 (81.0) 48 (71.0) 103 (75.8)
Total of episodes 68 (100.0) 68 (100.0) 136 (100.0)
Alive without Alive with Failure drug
Infection Evolution change change Death discontinuation
FUO 47 (34.6%) 39 (83%) 6 (12.8%) 2 (4.3%) 0 (0%)
Clin. Doc. 66 (48.5%) 57 (86.4%) 8 (12.1%) 0 (0%) 1 (1.5%)
Microb. Doc. 23 (16.9%) 7 (30.4%) 11 (47.8%) 3 (13.0%) 2 (8.7%)
Total 136(100.0%) 103 (76%) 25 (18%) 5 (4%) 3 (2%)
FUO: Fever of Unknown Origin; Clin. Doc: Clinically Documented Infection; Microb. Doc.: Microbiologically Documented
Infection.
Ceftriaxone + Amikacin Ticarcillin/Clavulanic acid
N (%) N (%)
Success* 63 (93.0 65 (96.0)
Without modification 55 (81.0) 48 (71.0)
With modification 8 (12.0) 17 (25.0)
Failure 2 (3.0) 5 (7.9)
Initial therapy changed 3 (4.8) 1 (1.0)
Death 3 (4.0) 2 (3.0)
Total 68 (100.0 68 (100.0)
* p = 0.716.
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in the first 72 hours, and in the overall evaluation (p =
0.059).
According to the status of the infection at the end of
treatment, in episodes diagnosed as FUO or Infection
Clinically Documented, the patients survived and needed
no change in the empirical therapy in 83% and 86% of
the cases, respectively. In episodes classified as
Microbiologically Documented Infections, the patients
survived, but more frequently needed changes in the initial
therapy (48%); 13% of these patients died (Table 8).
Therapeutic success occurred in 93% (63/68) of
the episodes in the C+A group and 96% (65/68) of
the T group (p = 0.716). Among these, eight cases
(12%) in the C+A group and 17 (25.0%) in the T group
needed a modification in the initial empiric antibiotic
regimen (p = 0.174). Five children died, three in the
C+A group and two in the T group. The cause of death
was therapeutic failure in three children (two in the C+A
and one in the T group) and disease progression in one
case in each group (Table 9).
Discussion
Onset of fever in a neutropenic patient is always an
indication of a possibly serious bacterial infection.
Patients with acute leukemia and stage III and IV
lymphomas have a higher risk for infectious
complications [1,3]. Underlying disease and intensive
chemotherapy leads to a prolonged neutropenia, a
greater frequency of bacteremia, secondary infection,
and a risk of death 10 times higher than the patients
classified as low-risk (solid tumors and stage I & II
lymphomas) [5,7]. These data from different studies
allowed low-risk patients to be treated in an ambulatory
setting, and emphasized the need of more attention for
high-risk patients [6,16-19].
The use of ceftriaxone plus amikacin has been
evaluated in this group of high-risk patients with
satisfactory results. Because of its broad spectrum
antimicrobial activity and low toxicity, Ticarcillin/
Clavulanic acid may be used as monotherapy in cancer
patients [10,12,15,17]. In adult patients with
granulocytopenia and fever there are studies describing
the use of Ticarcillin/Clavulanic acid with
aminoglycosides as an initial empirical therapy
[10,12,20,22-24]. Ticarcillin/Clavulanic acid and
tobramycin were used successfully in 72% of the Gram-
positive infections and 90% of the Gram-negative
infections in adults in a study by Krieger et al. [21].
Schaison et al. used Ticarcillin/Clavulanic acid with
netilmycin with success in 87% of the episodes in
children with fever and neutropenia secondary to cancer
treatment [23].
In another study of children with fever and
neutropenia, Yu et al. used Ticarcillin/Clavulanic acid
and gentamicin successfully in 88% of the cases, without
serious toxicity or fatality. Vancomycin was added in 8
of the 17 cases in which Gram-positive bacteria were
isolated [10]. In a more recent study, Gilbert et al.
compared Ticarcillin/Clavulanic acid, with gentamicin
as single daily dose or divided three times a day in 175
patients hospitalized with serious infections, evaluating
the safety and efficacy of a dose of gentamicin according
to creatinine clearance. Clinical and microbiological
efficacy were similar [25]. This association is an
important recommendation as initial therapy for patients
with serious infections [17].
In our study, 57% of the cases occurred in patients
with ALL and 21% in AML, with an average time of
neutropenia of  7.6 days in the C+A group and 8.7
days in the T group, which is comparable to our former
studies [5].
In the final evaluation, 73.6% of the patients were
defined as documented infections and 26.4% as FUO;
these rates are lower than those observed in our former
studies, and in the literature [5,7,21,23]. Of the 47 cases
of FUO initially found in 72 hours, 36 remained FUO,
8 evolved to be microbiologically documented and 3
to clinically documented infection. Among the patients
with clinically documented infections, the site of infection
most frequently found was the head and neck (59,
43%); there were 29 (43%) in the C+A group and 30
(44%) in the T group. The most frequently documented
infections were: mucositis, sinusitis, tonsillitis and otitis,
which is different from what is found in adults [5,6,7,8].
The addition of another antimicrobial agent was
necessary in 35 (51.5%) episodes in the T group and
28 (41.2%) in the C+A group. The most frequently
Ticarcillin versus Ceftri/Amika for Fever/Neutropenia
BJID 2003; 7 (April) 119
used drugs were amphotericin B and vancomycin.
Among the 22 (16.2%) episodes in which amphotericin
B was associated, fungi were isolated in 5. In 17 cases,
clinical deterioration and/or clinical evidence of fungal
infection was the reason for the empirical addition of
this antimicrobial agent.
Vancomycin was added in 7 (10.3%) episodes in the
C+A group (in 5 a Gram-positive pathogen sensitive to
vancomycin was recovered and in 2 there was a clinical
deterioration). In the T group, there were 11 (16.2%)
indications, 9 for Gram-positive pathogen isolation and 2
because of clinical deterioration. The addition of
vancomycin in only 13.2% of the episodes confirms the
non-indication for its use in initial empirical treatment.
These additions are not considered failure of the
initial empiric regimen; rather they are a consequence
of serious and prolonged neutropenia. The persistence
of fever after the beginning of an empiric antibiotic
regimen can demonstrate inadequate treatment of the
infection or the development of a secondary infection.
Documented infections after 72 hours of antibiotic
therapy were defined as secondary infections and were
diagnosed in 9 (13.2%) cases of the C+A group and
10 (14.7%) of the T group (Table 6 and 7).
Side effects found in the T group were not related to
the drug itself but to the underlying disease and its
complications (gastritis, arterial hypertension, diarrhea and
vomiting). No toxicity was observed in the C+A group.
These data agree with previous studies [5,8,9].
Five deaths occurred during this study, three in the
C+A group (two due to therapeutic failure and one due to
disease progression). One patient with acute myeloid
leukemia, had fever and diarrhea and a blood culture in
which Salmonella sp. was isolated. She progressed to
septic chock and death. The second patient, with AML in
the induction phase, developed pneumonia, skin abscess,
and diarrhea; coagulase negative Staphylococcus and
Candida guilliermondii were isolated in his blood. He
progressed to septic chock and death. The third patient,
with ALL in second marrow relapse, died from disease
progression and central nervous system bleeding.
Two deaths occurred in the T group, one from
central nervous system bleeding in a patient with AML,
the second death involved a patient with ALL in third
marrow relapse, who had bleeding and fungal infection
in the blood.
Overall success was documented in 96% and 97%
of the C+A and T groups, respectively. Success without
modification was 81% in the C+A group and 71% in
the T group, confirming that the drugs were adequate
for initial therapy.
The group of patients with microbiologically-
documented infection required more additions to the
initial empiric therapy, scoring an index of success
without changes of 30.4%, and 87.0% therapeutic
success with modification, which is similar to what was
found in other studies [10-12,20-24] (Table 8).
Conclusion
There was no toxicity associated with the drugs in
this study. Therapy was well tolerated. Monotherapy
with Ticarcillin/Clavulanic acid was as successful as the
combination of ceftriaxone plus amikacin. In children
and adolescents it should be considered an appropriate
option for patients at high risk for infection.
This data is from a pediatric oncology center in a
developing country, demonstrating that with effective
antimicrobial therapeutic strategies and adequate clinical
care it is possible to obtain results similar to those found
in more privileged centers, offering an opportunity for
more intense chemotherapy regimens and better survival
rates for the patients.
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